New Data Demonstrates Significant Clinical and Quality-of-Life Benefits of Flexitouch® Plus in Treating Lymphedema Among Head and Neck Cancer Survivors

Core Insights - Tactile Systems Technology, Inc. presented new clinical data at ASCO 2025 Annual Meeting, highlighting significant benefits of Flexitouch Plus in treating head and neck cancer-related lymphedema compared to usual care [1][2] Company Overview - Tactile Medical focuses on developing at-home therapies for chronic conditions such as lymphedema, chronic venous insufficiency, and chronic pulmonary disease, aiming to improve patient quality of life and reduce healthcare costs [4] Clinical Trial Findings - The study involved 236 subjects and is the largest randomized controlled trial for head and neck cancer survivors in the U.S. [2] - Two-month data indicated that usual care and advanced pneumatic compression device (APCD) are similarly effective, but APCD showed faster initiation of therapy and better quality-of-life outcomes [3][5] - APCD participants began treatment in an average of 17.9 days, compared to 29.8 days for usual care participants [5] - 94.9% of APCD participants received therapy, versus 71% in the usual care group [5] - APCD demonstrated significant reductions in swelling and improved health-related quality-of-life scores compared to marginal improvements in usual care [5] Future Expectations - The company anticipates that the six-month results from the trial will support broader reimbursement coverage, inform clinical guidelines, and enhance awareness among patients and providers [3]